Cybin announces additional u.s. patent supporting its cyb004 program in phase 2 development for generalized anxiety disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the united states patent and trademark office has granted u.s. patent 12,318,477 in support of its cyb004 deuterated dmt program in development for the treatment of generalized anxiety disorder (“gad”). the p.
CYBN Ratings Summary
CYBN Quant Ranking